First Light Asset Management LLC Acquires New Position in Ascendis Pharma A/S (NASDAQ:ASND)

First Light Asset Management LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 36,157 shares of the biotechnology company’s stock, valued at approximately $4,931,000. First Light Asset Management LLC owned about 0.06% of Ascendis Pharma A/S at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 1.1% during the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after acquiring an additional 44,580 shares in the last quarter. Capital International Investors lifted its holdings in shares of Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after acquiring an additional 10,044 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after purchasing an additional 93,185 shares in the last quarter.

Analyst Ratings Changes

ASND has been the subject of a number of recent research reports. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Wells Fargo & Company raised their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Jefferies Financial Group boosted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $195.00.

Ascendis Pharma A/S Price Performance

ASND stock opened at $146.60 on Tuesday. The stock has a market cap of $8.54 billion, a PE ratio of -15.25 and a beta of 0.63. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The firm has a 50 day simple moving average of $133.75 and a two-hundred day simple moving average of $136.50.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.